MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF), a biotechnology company commercializing AI-driven voice technology for drug and alcohol intoxication detection, is broadening the scope of its platform with the development of a fatigue prediction model designed for high-risk workplace environments. The company announced May 11 that it has developed a fatigue recognition system using speech analytics and proprietary artificial intelligence models, according to a news release.
The fatigue detection capability is expected to become an additional feature within MindBio’s planned Edge AI Intoxication Detection Kiosks, which are being designed to identify signs of impairment without requiring invasive biological samples. By incorporating fatigue monitoring, the platform aims to address a broader spectrum of safety risks in industries such as mining, aviation, transportation, and construction.
MindBio has filed a patent application covering detection of neurologically active substances and fatigue through voice analysis. The company is positioning its technology as a non-invasive alternative to breath, saliva, blood and laboratory-based testing systems. Management says commercial testing of kiosk hardware and software remains on track for late Q2 2026.
This expansion comes amid growing recognition of fatigue as a major factor in workplace accidents. According to the National Safety Council, fatigue-related incidents cost U.S. employers more than $136 billion annually in health-related lost productivity. By enabling real-time voice-based screening, MindBio’s technology could help employers proactively manage fatigue before it leads to incidents.
The company’s AI voice platform analyzes subtle changes in speech patterns that correlate with cognitive impairment from substances or exhaustion. The same edge computing architecture used for intoxication detection will support the fatigue module, allowing for on-device processing that ensures data privacy and low-latency results.
InvestorWire, a wire service that distributed the announcement, noted that the latest news and updates relating to MBQIF are available in the company’s newsroom at https://ibn.fm/MBQIF. MindBio Therapeutics continues to advance its technology toward commercial deployment, aiming to reduce workplace accidents and improve safety compliance.
The integration of fatigue detection into MindBio’s kiosks could give the company a competitive edge in the workplace safety market, which is increasingly focused on continuous, non-invasive monitoring. As regulatory bodies and labor organizations push for stronger fatigue management programs, voice analytics offers a scalable solution that can be deployed across multiple sites without the logistical burden of traditional testing methods.